Cwm LLC Has $2.24 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Cwm LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 203.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,507 shares of the medical equipment provider’s stock after buying an additional 16,429 shares during the quarter. Cwm LLC’s holdings in Zimmer Biomet were worth $2,235,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. Brighton Jones LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $204,000. GAMMA Investing LLC grew its holdings in Zimmer Biomet by 52.4% in the 1st quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock valued at $396,000 after buying an additional 1,204 shares in the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Zimmer Biomet by 0.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock worth $2,903,000 after purchasing an additional 118 shares in the last quarter. QRG Capital Management Inc. grew its holdings in shares of Zimmer Biomet by 13.9% during the 1st quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider’s stock worth $767,000 after purchasing an additional 827 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC grew its holdings in shares of Zimmer Biomet by 20.0% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 435 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $102.00 on Friday. The stock’s 50-day simple moving average is $101.74 and its 200 day simple moving average is $97.78. The firm has a market capitalization of $20.21 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 2.35 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ZBH. Royal Bank Of Canada set a $111.00 target price on Zimmer Biomet in a report on Friday, October 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Evercore ISI reduced their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a report on Tuesday, October 7th. Finally, UBS Group increased their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $111.94.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.